Business Context and Reporting Period
Company: KALA BIO, Inc. (KALA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: KALA BIO is a biopharmaceutical company in strategic transition. Following the failure of its lead product candidate, KPI-012, to meet primary endpoints in the CHASE Phase 2b clinical trial in September 2025, the Company ceased development of its mesenchymal stem cell secretome (MSC-S) platform. The Company has pivoted to a dual-track strategy: (1) monetizing its legacy biologics asset portfolio (KPI-012 and KPI-014) through licensing or sale, and (2) developing "Researgency," an on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry, secured via an exclusive license from Younet AI in March 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(27.0) million | $(38.5) million |
| Operating Expenses | $39.2 million | $41.0 million |
| Cash and Cash Equivalents (Year-End) | $7.6 million | $51.2 million |
| Accumulated Deficit | $(694.9) million | $(667.9) million |
| Debt Outstanding (Year-End) | $0 | $29.3 million |
| Employees (Year-End) | 6 | ~37 (pre-reduction) |
Note: The filing text does not provide specific gross margin or operating margin percentages due to the absence of revenue.
Material Changes vs. Prior Period
- Clinical Trial Failure: The CHASE Phase 2b trial for KPI-012 failed to meet primary and key secondary endpoints in September 2025, leading to the suspension of all clinical development for the MSC-S platform.
- Debt Resolution: The Company resolved a default under its senior secured credit facility with Oxford Finance LLC. A settlement was reached in November 2025, and the remaining debt obligation was fully satisfied in December 2025, resulting in a $5.8 million gain on extinguishment of debt.
- Workforce Reduction: Following the trial failure and debt default, the Company reduced its workforce by approximately 51% in September 2025 and terminated substantially all remaining employees in October 2025. As of the filing date, the Company had only 3 full-time employees.
- Leadership Turnover: Significant changes occurred in executive leadership and the Board of Directors throughout 2025 and early 2026, including the resignation of the former CEO and the appointment of new leadership (Avi Minkowitz as CEO/CFO) in February 2026.
- Capital Structure: The Company raised capital through a Registered Direct Offering ($10.0 million) in December 2025 and private placements of Series AA and Series AAA Preferred Stock (totaling $6.0 million) in late 2025 and early 2026.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company expects to fund operations into the first quarter of 2027 with its current cash balance of $7.6 million. The primary focus is the development and commercialization of the Researgency AI platform, utilizing the Company's proprietary KPI-012 clinical dataset as a proof-of-concept. The Company is also actively seeking strategic partners to monetize its biologics IP.
Key Risks and Contingencies:
- Going Concern: While management concluded that substantial doubt about the Company's ability to continue as a going concern was alleviated as of the filing date due to recent financing and debt resolution, the Company has a history of recurring losses and negative cash flows. Continued access to capital is critical.
- Nasdaq Compliance: The Company received deficiency notices from Nasdaq regarding the Minimum Market Value of Listed Securities (MVLS) and Minimum Bid Price requirements. It has 180-day compliance periods to regain compliance or face potential delisting.
- AI Platform Execution: The Company has no revenue from the Researgency platform and limited experience in developing AI technology. Success depends on customer adoption of on-premises AI solutions and the performance of the third-party licensor, Younet AI.
- Intellectual Property: The biologics portfolio relies on patents exclusively licensed from Stanford University. Termination of these licenses or failure to maintain them would materially harm the Company's asset value.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $7.6 million cash balance and the projected burn rate to confirm the ability to fund operations through Q1 2027.
- Nasdaq Status: Monitor the Company's progress in regaining compliance with Nasdaq listing standards (MVLS and Bid Price) by the May 11, 2026, and July 20, 2026, deadlines.
- Researgency Progress: Assess the status of the Younet AI license agreement, the deployment of the Researgency platform, and any initial customer engagements or pilot programs.
- Biologics Monetization: Track any announcements regarding licensing deals, collaborations, or sales of the KPI-012/KPI-014 intellectual property portfolio.
- Capital Raises: Monitor the utilization of the new At-The-Market (ATM) facility and any further private placements required to sustain operations beyond the current runway.